Document Detail


Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
MedLine Citation:
PMID:  1588379     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: A randomized study comparing low-dose aminoglutethimide (AG) with and without hydrocortisone (HC) was performed to investigate whether corticosteroid replacement contributes to the therapeutic effects of the drug administered as a front-line endocrine therapy in postmenopausal advanced breast cancer. PATIENTS AND METHODS: Postmenopausal patients who had not had prior endocrine therapy for advanced disease and with estrogen receptor (ER) or progesterone receptor (PgR) status positive or unknown were eligible. AG was administered at a dose of 250 mg twice a day orally (125 mg twice a day during the first month) with or without HC (20 mg twice a day orally). Seventy-nine and 74 patients were assessable for response on the AG plus HC arm and on the AG arm, respectively. The two treatment groups were well balanced and patients were largely untreated. Approximately 60% had not received any adjuvant treatment, and approximately 75% had not received any medical treatment after relapse. RESULTS: The overall responses (complete response [CR] plus partial response [PR]) were 44% and 41% for the AG plus HC and the AG arm, respectively, showing no significant difference. Time to progression (median, 8.1 and 6.3 months), duration of response (median, 15.8 and 13.7 months), and duration of survival (median, 34.2 and 36.3 months) were not significantly different between the two treatment arms. Side effects were infrequent and mild in both arms, with no significant differences. CONCLUSION: We conclude that half of the conventional daily dose of AG has optimal therapeutic activity as a front-line endocrine treatment of postmenopausal advanced breast cancer and that HC does not significantly contribute to the therapeutic effects.
Authors:
G Cocconi; G Bisagni; G Ceci; M Bacchi; C Boni; M Brugia; A Carpi; F Di Costanzo; V Franciosi; S Gori
Related Documents :
21821499 - Clinical significance of intestinal type fatty acid binding protein in patients undergo...
8273539 - Patient satisfaction with reduction mammaplasty: an early survey.
20472269 - Does severity of renal scarring on dmsa scan predict abnormalities in creatinine cleara...
21031069 - Novel technology in the treatment of acne scars: the matrix-tunable radiofrequency tech...
24682079 - A prospective randomized observer-blinded study to assess postoperative analgesia provi...
23440619 - Femoral remodeling around charnley total hip arthroplasty is unpredictable.
20653619 - A systematic review of the effectiveness of smoking relapse prevention interventions fo...
24477709 - Cardiopulmonary exercise testing for preoperative risk assessment before pancreaticoduo...
22373499 - Effect of feedback on delaying deterioration in quality of compressions during 2 minute...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  10     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  1992 Jun 
Date Detail:
Created Date:  1992-06-25     Completed Date:  1992-06-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  984-9     Citation Subset:  IM    
Affiliation:
Medical Oncology Service, University Hospital, Parma, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy*
Adult
Aged
Aged, 80 and over
Aminoglutethimide / administration & dosage*,  adverse effects
Breast Neoplasms / drug therapy*
Drug Therapy, Combination
Female
Humans
Hydrocortisone / administration & dosage*,  adverse effects
Middle Aged
Prospective Studies
Chemical
Reg. No./Substance:
125-84-8/Aminoglutethimide; 50-23-7/Hydrocortisone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the brea...
Next Document:  Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors.